Compare ACRE & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRE | SIGA |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 223.8M |
| IPO Year | 2011 | 2016 |
| Metric | ACRE | SIGA |
|---|---|---|
| Price | $3.68 | $3.10 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 648.5K | 468.9K |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | 17.65% | ★ 20.20% |
| EPS Growth | ★ 26.17 | N/A |
| EPS | ★ 1.35 | 0.13 |
| Revenue | ★ $54,833,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.53 | $170.70 |
| P/E Ratio | ★ $2.60 | $24.23 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.16 | $2.83 |
| 52 Week High | $5.89 | $7.11 |
| Indicator | ACRE | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 58.05 | 46.13 |
| Support Level | N/A | $3.02 |
| Resistance Level | $4.98 | $3.32 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 84.46 | 38.60 |
Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.